Stryker (SYK) Earnings Call Highlights Growth and Resilience

Stryker Corp ((SYK)) has held its Q4 earnings call. Read on for the main highlights of the call.

Stryker’s Earnings Call Signals Confidence Despite Tariff and Rate Headwinds

Stryker Corp’s latest earnings call carried a clearly upbeat tone, underscoring broad-based strength in sales, profitability, and cash generation. Management highlighted record momentum in its Mako robotics platform, continued operating margin expansion, and strong demand across key product lines, while openly acknowledging manageable challenges from tariffs, higher interest expense, competitive pressure in parts of its vascular business, and some regional capital softness. Overall, the message was one of durable growth, expanding profitability, and ample financial flexibility heading into 2026.

Strong Top-Line Growth Across Geographies

Stryker delivered double-digit organic growth, with Q4 organic sales up 11.0% and full-year 2025 organic sales up 10.3%, pushing total sales above $25 billion. The U.S. remained the growth engine, posting 11.2% organic growth for the year, while international markets delivered a solid 7.5%. This performance reflects resilient procedure volumes and robust customer demand despite macro uncertainty, positioning Stryker as one of the faster-growing large-cap medtech names.

MedSurg & Neurotechnology Leads Segment Outperformance

The MedSurg & Neurotechnology segment was a standout, reporting Q4 organic growth of 12.6%, with the U.S. up 13.0% and international markets up 10.9%. Instruments, endoscopy, and core medical products drove this outperformance, showcasing the strength of Stryker’s diversified portfolio. Management emphasized that MedSurg continues to benefit from strong operating room demand, product innovation, and hospital customers prioritizing solutions that improve efficiency and workflow.

Instruments and Endoscopy Show Robust Momentum

Within MedSurg, instruments and endoscopy delivered particularly strong results. U.S. organic instruments sales grew 19.1%, supported by high-teens growth in orthopedic instruments and Surgical Technologies. U.S. endoscopy sales rose 11.1%, propelled by adoption of sustainability offerings and sports medicine camera and platform solutions. These trends highlight hospitals’ willingness to invest in technologies that enhance visualization, efficiency, and cost savings, reinforcing the durability of Stryker’s growth in these categories.

Robotics Leadership Solidified by Mako 4 Performance

Robotics remained a core strategic pillar, with Stryker reporting a record quarter for Mako installations and an installed base now exceeding 3,000 systems worldwide. In the U.S., more than two-thirds of knee procedures and over one-third of hip procedures are now performed using Mako, while globally roughly half of knees and more than 20% of hips utilize the platform. Mako 4 and new applications are driving increased adoption and utilization, strengthening Stryker’s first-mover advantage in orthopedic robotics and creating a recurring revenue tailwind from associated implants and disposables.

Orthopaedics Benefits from New Products and Mako Synergy

Orthopaedics posted healthy 8.4% organic growth, with U.S. growth of 9.6% and international growth of 5.4%. In the U.S., knees grew 7.6% and hips 5.6%, while Trauma & Extremities rose 8.5%. The “Other ortho” category surged 28.7%, reflecting traction from Mako 4 installations and new launches such as the limited rollout of the Triathlon Gold knee system. The combination of robotics pull-through and refreshed implant portfolios is helping Stryker defend and expand share in a competitive ortho market.

Margin Expansion and Double-Digit EPS Growth

Stryker converted strong revenue growth into bottom-line gains, with Q4 adjusted EPS climbing 11.5% year over year to $4.47 and full-year adjusted EPS rising 11.8% to $13.63. Adjusted operating margin reached 30.2%, a 100-basis-point improvement versus the prior year, marking the second consecutive year of at least 100 basis points of margin expansion. Management highlighted ongoing productivity initiatives and operating leverage as key margin drivers, signaling confidence in the company’s ability to continue expanding profitability even amid cost pressures.

Robust Cash Flow Underpins Balance Sheet Strength

Cash generation remained a key highlight. Year-to-date cash from operations reached $5.0 billion, an increase of $820 million versus the prior year. Free cash flow conversion improved to 81% of adjusted net earnings, above the company’s target range of 70–80%. This strong cash performance, coupled with an already solid balance sheet, gives Stryker meaningful financial “firepower” for continued M&A, strategic investments, and potential capital deployment while supporting its long-term growth algorithm.

Tariff Headwinds Weigh on Gross Margin

Management called out tariffs as a growing headwind, expecting approximately $400 million of tariff impact in 2026, including an incremental $200 million versus 2025 that will largely hit in the first half. In Q4, tariffs contributed to a 10-basis-point decline in adjusted gross margin. While the company is pursuing mitigation levers, this represents a notable cost overhang that could partially offset efficiency gains and margin expansion if not fully absorbed or passed through.

Higher Interest Expense Pressures Other Income/Expense

Stryker’s adjusted other income/expense line moved against it in the quarter, coming in at $107 million, or $56 million worse than the prior year, primarily due to higher interest expense from debt issuance and lower interest income. Looking forward, management expects full-year 2026 other income/expense to be around $420 million. This higher interest burden modestly dampens EPS growth leverage but is manageable given the company’s strong operating performance and cash flow.

Vascular Ischemic Facing Competitive Pressure

In the vascular business, U.S. organic sales grew 4.3%, with strong hemorrhagic performance offset by competitive dynamics in the ischemic segment. Peripheral vascular, including Inari, saw high-teens procedural growth, but this was partially offset by customer destocking. While the underlying procedure trends remain favorable, the competitive and inventory backdrop in ischemic is creating near-term volatility and moderating reported growth.

Destocking and Inventory Timing Effects

Management noted that peripheral (Inari) experienced more destocking in Q4 than initially anticipated, which weighed on reported growth despite robust procedure volumes. They expect destocking to be minimal in Q1 2026, suggesting that some of the pressure was temporal and related to inventory timing rather than underlying demand. Investors should watch subsequent quarters to confirm that growth normalizes as inventory levels rebalance.

European Capital Spending Softness

The company flagged a softer capital environment in Europe during the quarter, which constrained international capital growth. Additionally, certain product launches have been delayed by regulatory and timing issues, including the impact of EU Medical Device Regulation (MDR) requirements. While these factors present a regional headwind, management’s commentary implied that the softness is not structural, but it could continue to weigh on international growth and capital equipment orders in the near term.

Mixed Pricing Dynamics Across Businesses

Pricing remained modestly positive at the enterprise level, but trends diverged by business. MedSurg pricing was described as positive, helped by differentiated technology and value propositions, while Orthopaedics pricing is expected to be slightly negative, in line with typical market pressure in implants. Net-net, management anticipates a pricing contribution similar to 2025, with mix and volume doing the heavy lifting for growth rather than price.

Supply Constraints and One-Time Tax Effects

Stryker acknowledged that supply constraints persisted through 2025 but are not expected to materially impact results in 2026. The company also noted that discrete tax items and geographic mix effects contributed to a Q4 adjusted effective tax rate of 16.1%, modestly pressuring EPS comparisons. These factors are seen more as one-off or transient items rather than ongoing structural issues.

Constructive 2026 Guidance and Market Outlook

For 2026, Stryker guided to organic net sales growth of 8.0%–9.5% and adjusted net EPS of $14.90–$15.10, implying continued healthy top-line expansion and double-digit earnings growth potential. The company expects pricing to be modestly positive overall and anticipates a slightly favorable foreign exchange effect if current rates hold. Management assumes the same number of selling days and seasonality patterns as 2025, while baking in a roughly $400 million full-year tariff headwind and about $420 million of other income/expense. The effective tax rate is expected to be 15%–16%, and free cash flow conversion is targeted at 70–80% of adjusted net earnings under its long-range plan. Despite tariffs and higher interest costs, Stryker projects sustained procedure volumes, solid hospital capital spending, and an elevated capital order book entering 2026, all supporting a confident outlook.

In sum, Stryker’s earnings call painted a picture of a company firing on most cylinders: robust organic growth, expanding margins, strong cash generation, and clear strategic advantages in robotics and MedSurg. While tariffs, interest expense, vascular competition, and European capital softness represent real but manageable headwinds, management’s guidance and tone suggest they are well positioned to navigate these challenges. For investors, the story remains one of durable growth backed by innovation, operational discipline, and substantial financial flexibility.